


Journal Pre-proof

Tildrakizumab 200 mg. Is double dosing really a window of opportunity?

Carlos Llamas-Segura MD Marta Cebolla-Verdugo MD Ricardo Ruiz-Villaverde PhD



PII: S0001-7310(25)00815-4

DOI: <https://doi.org/doi:10.1016/j.ad.2025.104539>

Reference: AD 104539

To appear in: *Actas dermosifiliograficas*

Received Date: 2 October 2024

Accepted Date: 23 May 2025

Please cite this article as: Llamas-Segura C, Cebolla-Verdugo M, Ruiz-Villaverde R, Tildrakizumab 200 mg. Is double dosing really a window of opportunity?, *Actas dermosifiliograficas* (2025), doi: <https://doi.org/10.1016/j.ad.2025.104539>

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: <https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article>. Please also note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 AEDV. Published by Elsevier España, S.L.U.

Foro de residentes

Tildrakizumab 200 mg. Is double dosing really a window of opportunity?

FR- Tildrakizumab 200mg ¿Es realmente una ventana de oportunidad la doble dosis?

Autores: Carlos Llamas-Segura MD (1); Marta Cebolla-Verdugo MD(1); and Ricardo Ruiz-Villaverde (1) PhD

(1) Servicio de Dermatología, Hospital Universitario San Cecilio, Granada. Instituto Biosanitario de Granada (ibs.GRANADA), Spain

Corresponding author: Carlos Llamas-Segura, MD

E-mail address: car.llam.seg@gmail.com

Palabras clave: Psoriasis, terapia intensiva, tildrakizumab, anti-interleuquina 23

Tildrakizumab is a humanized IgG1/κ monoclonal antibody that binds specifically to the p19 subunit of the cytokine interleukin-23 (IL-23), thereby inhibiting its interaction with the receptor. According to its product information, the recommended dose is 100 mg by subcutaneous injection at weeks 0 and 4 and every 12 weeks thereafter; however, at the clinician's discretion, in patients with a high disease burden or in those weighing > 90 kg, a 200 mg dose may be more effective¹.

Tildrakizumab is the only IL-23p19 inhibitor that has approval for individualized, weight-adjusted dosing. Its introduction into our therapeutic arsenal was preceded by an evaluation of its tolerability and safety using a single 200 mg/2 mL subcutaneous injection². In that study, safety outcomes were similar to those obtained with 2 100 mg/L injections, and most participants preferred the double dose because of easier administration.

In real-world clinical practice, only 2 studies have reported experience with the 200 mg dose of tildrakizumab. Gargiulo et al.³ presented a 16-week retrospective multicenter study comparing both doses, including 134 patients treated with 200 mg and 364 treated with 100 mg. In the 200 mg group, the mean patient weight was 91.09 kg vs 79.95 kg in the 100 mg group. After 16 weeks, 57.5% of patients on 200 mg achieved PASI 90 vs 34.3% in the 100 mg group. Complete remission (PASI 100) was achieved by 39.6% of patients treated with 200 mg vs 24.2% of those treated with 100 mg. These results must be interpreted with caution due to the proximity to the weight threshold. We consider it necessary to re-evaluate the concept of disease burden in this context. Separately, Trovato⁴ studied 30 patients over 28 weeks with both doses and found significantly greater improvements in outcomes (WHO-5 and DLQI) among patients on the 200 mg dose.

In our Psoriasis Unit, we assessed the safety and efficacy outcomes of 8 patients—whose characteristics are summarized in Table 1—who at some point received the 200 mg dose during six months of follow-up. These findings support the data published in the above-mentioned clinical trials and observational studies (Figure 1). Four of the 8 patients began therapy at the standard dose and were subsequently escalated to the intensified dose due to either primary failure (failure to reach absolute PASI < 3 at week 16) or secondary failure (loss of absolute PASI < 3 after having achieved it). These 4 patients did not undergo dose escalation at the same follow-up visit.

In response to the initial question, we believe that a window of opportunity is opening not only for weight-based dose adjustment but also for patients with higher disease burden—understood as a greater number of comorbidities, involvement of difficult-to-treat areas, unsatisfactory response to several lines of biologic therapy, and high emotional impact—provided that accessibility maintains the same price for both doses. It would be desirable to evaluate direct costs and work productivity in daily practice, although systematic assessment of these aspects is currently far from being a reality⁵.

REFERENCES

1. Ficha técnica de Ilumetri® (tildrakizumab). Available at: https://www.ema.europa.eu/documents/productinformation/ilumetri-epar-product-information_es.pdf. (Accessed Oct 2024).
2. Kokolakis G, Kreis G, Falqués M, Aparici M, Sondermann W. High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers. *Dermatol Ther (Heidelb)*. 2022;12(9):2135-2144.
3. Gargiulo L, Ibba L, Cascio Ingurgio R, Malagoli P, Amoroso F, Balato A, et al. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis). *J Dermatolog Treat*. 2024;35(1):2350760.
4. Trovato E, Dragotto M, Capalbo E, Cartocci A, Rubegni P, Calabrese L. Uncovering the Differences: How DLQI and WHO-5 Scores Vary in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab 100 mg vs. 200 mg? *J Clin Med*. 2024;13(17):5240.
5. Puig L, Ferrándiz C, Pujol RM, Vela E, Albertí-Casas C, Comellas M, et al. Burden of Psoriasis in Catalonia: Epidemiology, Associated Comorbidities, Health Care Utilization, and Sick Leave. *Actas Dermosifiliogr (Engl Ed)*. 2021;112(5):425-433.




Figure 1. A. Progression of PASI and BSA from baseline to week 24 in our 8 patients. **B.** Progression of pruritus NRS and DLQI from baseline to week 24 in our 8 patients.

Table 1. Clinical Characteristics and Treatments Received by Patients in the Unit

Characteristics	Values
No. of patients	8
Sex, no. M/F	6/2
Age, years, mean (range)	48 (20–75)
BMI*, mean (range)	26.4 (19–37)
Weight, kg, mean (range)	80.4 (51–107)
Weight > 90 kg	3
Time since diagnosis, years, mean (range)	17 (2–56)
No. of affected sites, mean (range)	2.4 (1–4)
No. of previous biologics, mean (range)	1 (0–2)
Adalimumab	6
Ustekinumab	1
Secukinumab	1
Super-nonresponder**	1
Dosing*	
Initiation (weeks 0 and 4)	
Standard dose	4
Weight > 90 kg	2
Baseline PASI \geq 8	3
Intensified dose	4
Weight > 90 kg	1
Baseline PASI \geq 8	2
Maintenance (from week 4 onward)	
Standard dose	4
Weight > 90 kg	1
Baseline PASI \geq 8	2
Intensified dose	4
Weight > 90 kg	2
Baseline PASI \geq 8	3

*BMI: Body mass index.

**Super-nonresponder: Refractory to >3 previous biologics.

***Dosing: Standard dose = 100 mg subcutaneously at weeks 0 and 4, then every 12 weeks. Intensified dose = 200 mg following the same administration schedule.

Journal Pre-proof